ストックスクリーナーアプリを入手
246.80
1.57%
-3.93
前日終値:
$250.73
開ける：
$245
24時間の取引高:
623.47K
Relative Volume:
0.82
時価総額：
$17.94B
収益：
$1.98B
当期純損益:
$420.90M
株価収益率:
42.26
EPS:
5.84
ネットキャッシュフロー:
$218.20M
1週間 パフォーマンス:
-1.86%
1か月 パフォーマンス:
-5.67%
6か月 パフォーマンス:
+7.71%
1年 パフォーマンス:
+48.44%
1日の値動き範囲:
$234.22
$248.96
1週間の範囲:
$234.22
$258.00
52週間の値動き範囲:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
PODD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
246.80 | 17.94B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-11-06 | 開始されました | Bernstein | Outperform |
| 2024-05-30 | 開始されました | Redburn Atlantic | Buy |
| 2024-05-07 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-21 | アップグレード | Citigroup | Neutral → Buy |
| 2023-08-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 開始されました | Wolfe Research | Peer Perform |
| 2022-11-04 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-07-28 | 開始されました | Wells Fargo | Overweight |
| 2020-04-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 開始されました | BofA/Merrill | Neutral |
| 2020-03-31 | ダウングレード | Berenberg | Buy → Hold |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-10 | 開始されました | CFRA | Sell |
| 2019-10-23 | 開始されました | Stifel | Hold |
| 2019-10-18 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-10-04 | ダウングレード | UBS | Buy → Neutral |
| 2019-10-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-06-10 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-04-20 | 開始されました | Berenberg | Buy |
| 2018-02-22 | 繰り返されました | Barclays | Overweight |
| 2018-01-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 開始されました | Barclays | Overweight |
すべてを表示
Insulet Corporation (PODD) 最新ニュース
Study Data Show Significant Glycemic Improvements With Omnipod 5 - Medical Product Outsourcing
RBC Cuts Price Target on Insulet to $325 From $340, Keeps Outperform Rating - marketscreener.com
What's Driving the Market Sentiment Around Insulet? - Benzinga
Insulet Announces Proposal for Upcoming Financing Deals - The Healthcare Technology Report.
Schroder Investment Management Group Decreases Stake in Insulet Co. (NASDAQ:PODD) - MarketBeat
Insider Sell: Insulet - marketscreener.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? - Nasdaq
Insulet's Market Expansion: The Omnipod Impact on Diabetes Care - marketscreener.com
Insulet's $389 Million Trading Day Lands 450th in Market Rankings - AInvest
Ex-Insulet CTO Mark Field has a new job in medtech with ITJ - Medical Design & Outsourcing
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - MSN
MedTechVets Announces Veteran Placement Partnership with Insulet - WebWire
GE Vernova, Insulet lead modest stock rebound amid tariff volatility - The Business Journals
Automated Insulin Delivery Systems - Trend Hunter
Insulet (NasdaqGS:PODD) Launches Omnipod 5 In Canada As Shares Dip 7% - Yahoo Finance
Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above - The Malaysian Reserve
Citigroup Adjusts Insulet Price Target to $315 From $355, Maintains Buy Rating - marketscreener.com
Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet? - simplywall.st
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Insulin Tech Leader Insulet Readies Q1 2025 Results: What's Next for Omnipod Maker? - Stock Titan
(PODD) Trading Advice - news.stocktradersdaily.com
Insulet Stock: Is PODD Outperforming the Healthcare Sector? - Nasdaq
Insulet Stock: Is PODD Outperforming The Healthcare Sector? - Barchart.com
New Age Alpha Advisors LLC Buys Shares of 30,096 Insulet Co. (NASDAQ:PODD) - MarketBeat
3 Reasons Investors Love Insulet (PODD) - Yahoo Finance
Insulet director Frederick Wayne sells $501,875 in stock By Investing.com - Investing.com Canada
Insulet director Frederick Wayne sells $501,875 in stock - Investing.com
Insulet glows with RADIANT results, CGMs becoming T2D standard - BioWorld MedTech
Insulet Gains 62.9% in a Year: What's Driving the Stock? - Yahoo
Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5% - Yahoo Finance
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Insulet Corp issues $450 million in senior notes By Investing.com - Investing.com Canada
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Com - GuruFocus
PODD Stock Gains Following the Launch of Omnipod 5 in Australia - Yahoo Finance
Insulet Corp issues $450 million in senior notes - Investing.com India
Insulet Closes $450 Million Senior Notes Issuance - TipRanks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers - Yahoo Finance
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 - Nasdaq
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day - TradingView
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - BioSpace
Insulet's RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition - Nasdaq
Omnipod 5 improves diabetes control in clinical trial By Investing.com - Investing.com South Africa
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections - Lelezard
Insulet says data shows significant glycemic improvement with Omnipod 5 - Seeking Alpha
Insulet Reports Glycemic Improvements With Omnipod Automated Insulin Delivery System - Marketscreener.com
Insulet Corporation (PODD) 財務データ
収益
当期純利益
現金流量
EPS
1.01%
0.46%
大文字化:
|
ボリューム (24 時間):